Price Alert

Praxis Precision Medicine... (PRAX)

NASDAQ: PRAX · Real-Time Price · USD

189.99

27.28 (16.77%)

At close: Oct 17, 2025, 3:59 PM

188.20

-0.94%

After-hours: Oct 17, 2025, 07:57 PM EDT

16.77% (1D)

Bid	189
Market Cap	4B
Revenue (ttm)	7.76M
Net Income (ttm)	-251.01M
EPS (ttm)	-12.4
PE Ratio (ttm)	-15.32
Forward PE	-4.57
Analyst	Strong Buy
Dividends	n/a

Ask	191
Volume	4,401,399
Avg. Volume (20D)	672,403
Open	178.94
Previous Close	162.71
Day's Range	178.14 - 203.56
52-Week Range	26.70 - 205.89
Beta	2.64
Ex-Dividend Date	n/a

About PRAX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PRAX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PRAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Praxis Precision Medicines Inc. is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

9 hours ago New

Praxis Precision Medicines shares are trading high... Unlock content with Pro Subscription

1 day ago New

+183.71%

Praxis Precision Medicines shares are trading higher after the company released topline data from two pivotal Phase 3 trials of Ulixacaltamide HCl for essential tremor.

News

14 hours ago · invezz.com

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Praxis Precision Medicines (NASDAQ: PRAX stock) saw a skyrocketing 235% rally on Thursday after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tre...

19 hours ago · zacks.com

Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?

Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

1 day ago · seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program October 16, 2025 8:00 AM EDT Company Participants Marcio Souza - Preside...

1 day ago · marketwatch.com

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.

1 day ago · investors.com

The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200%

Shares of Praxis Precision Medicines skyrocketed more than 200% Thursday on "groundbreaking" test results for an essential tremor treatment.

1 day ago · reuters.com

Praxis Precision Medicines' movement disorder drug shows promise in trials

Praxis Precision Medicines said on Thursday its experimental drug for movement disorder helped improve daily functioning in patients in two late-stage trials.

2 weeks ago · businesswire.com

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, tod...

2 months ago · businesswire.com

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $PRAX--PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm.

2 months ago · seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants a - Corporate Participant Marcio Silva De'Souza - President, CEO & Direc...

2 months ago · fool.com

Praxis (PRAX) Q2 Loss Widens 90%